68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. - Wikidata - wikimedia - TriplyDB

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

http://www.wikidata.org/entity/Q39389586

about

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status Prostate-specific membrane antigen as a target for cancer imaging and therapy Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases [(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.Cancer stratification by molecular imaging.(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy New advances in focal therapy for early stage prostate cancer.New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with (68)Ga(3.).(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.Prospective of ⁶⁸Ga-radiopharmaceutical development.44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617.Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring.PET imaging in prostate cancer: focus on prostate-specific membrane antigen Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment.Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications.PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.Next revolution in molecular theranostics: personalized medicine for urologic cancers.Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative.⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling.

P2860

Q26747480-D9DAF41F-C79D-4D26-A815-1D01CE26A2DC Q26774920-CE5F8FC7-2BCF-4611-B1EB-A7E97667C6F4 Q26799439-4C368A79-7FEF-4BCE-8A66-DF9E57AA22E4 Q27025187-6B3B6F33-7E4D-4646-89CD-29B8F2BA3A20 Q30396825-36BC52CA-17DD-4468-84F0-F7027744BD1A Q31145236-00B3EA39-BDA4-4B50-8C34-3EBEFC04B744 Q33668676-EEE2C300-CE9A-40F8-AD4E-C2D1B7D776BD Q33699158-EB9618B9-AB4D-4DBC-A525-9FD83612F891 Q33711641-71C59AD5-690B-4DE9-A8F2-F9A2AE01D804 Q33802694-1749FF12-AADC-4B89-B30F-2558FABC6C03 Q33914844-716E5A65-4B6F-4576-9C8D-A3C3DBA9BD5C Q35043569-0BDA6925-D8C6-4201-901E-21C8EFC37326 Q35380664-3C14D724-F9CB-4ABC-B598-C925DC0EF4F9 Q35877470-53E49B7E-1FAF-40D7-9A51-5735332D0239 Q35938051-C8951939-276E-464E-8618-DC673A6553EE Q36143456-7A254F75-FF03-4991-9EB5-D55A82103E45 Q36289592-48F41B28-B0E7-4DB9-81E2-6B1C12353D53 Q36411076-E1C143C8-B108-4B6D-A5D9-59E1EDEE0402 Q36595679-C5138BC3-964F-4F1B-A73E-F62C128ECC73 Q36632690-242CCA49-0BD7-4DEF-A074-C538DE79CB0B Q36867784-4A1777AB-5E99-41FF-B151-06F7A3516DFD Q36999897-A2791D75-0C8C-46DD-BF78-1A3C2D8AF273 Q37214430-FAFB0F46-0B81-48E1-B82C-B41F223268EC Q37350456-3F954093-8AFC-436B-BF5D-EF21DE22F46A Q37435222-4EA36148-D916-4B46-B4A3-D350DC14B7AF Q37594922-39EB5335-498E-4C6B-A5CC-C368F0ECE3A1 Q37623394-75A8F9A8-588B-4BF6-AAE3-BAC0350DC68D Q37709519-A0F81D92-B180-4AB5-A7DB-5D35B12AE554 Q37714485-36A6A4DD-DBDB-4A4C-B6FF-0446DF8F20A5 Q38099369-99DEBC94-6BE6-4744-B17A-92667AEEB045 Q38167022-6FB252B0-7B25-4BB5-937D-32D283E7E6D8 Q38178849-20FF782E-EF8F-45EB-8C1B-2C8D1FFDD537 Q38202090-644BCB91-C1D2-465D-9261-8CE865EF83FA Q38389152-2F9CDE23-E327-477F-8004-C4725DD1F8D3 Q38559336-787376DA-46F7-4220-9D02-213327423124 Q38619857-67DA127F-36DF-42C2-9D2D-4DAEAB31EC2A Q38639486-07E86E38-4798-48A0-98D7-95A1A1D12F71 Q38641232-524B35BF-E483-486B-B9F1-AD105A2BCF8A Q38705627-33884B12-2DBB-44D5-BAE5-081E10DC51CF Q38707752-0A552E0C-8F44-4BFA-BD8D-7A3302A812DE

P2860

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

http://www.wikidata.org/entity/Q39389586

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

68Ga-complex lipophilicity and ...... SMA inhibitor for PET imaging.

@en

68Ga-complex lipophilicity and ...... SMA inhibitor for PET imaging.

@nl

type

label

68Ga-complex lipophilicity and ...... SMA inhibitor for PET imaging.

@en

68Ga-complex lipophilicity and ...... SMA inhibitor for PET imaging.

@nl

prefLabel

68Ga-complex lipophilicity and ...... SMA inhibitor for PET imaging.

@en

68Ga-complex lipophilicity and ...... SMA inhibitor for PET imaging.

@nl

P1433

Q39389586-2E4CC05C-5C11-4CE8-BA09-DC403AFDE992

P1476

Q39389586-B291E498-6B82-41F5-9922-BBDDC8EA2448

P2093

Q39389586-2EE5DA7E-9CC0-4AAF-843D-6D4CE9157C74

Q39389586-34532DEF-247D-4E50-95C7-1C2EAAD785D0

Q39389586-3AFB757D-0AF5-4EBB-8FE5-74749EE21C69

Q39389586-3B14DA1D-892E-48E6-906E-D046C3C85894

Q39389586-7A7F7F02-C887-4387-9D4E-1E03109190F6

Q39389586-AFC90A00-BBD5-4EEB-AD15-E522156CF0FC

Q39389586-DF53CA86-C792-4CEC-971C-B94D74E50D6B

P304

Q39389586-C10D4535-E7AD-4F08-B047-26ABA1A9B7BA

P31

Q39389586-D5B8632B-A9B0-4053-A5F1-11E0A606129F

P356

Q39389586-CB853C16-FB72-4CBE-9E5B-8805C1FC2A38

P433

Q39389586-46614CD2-A87E-46FF-A043-A22B3B753352

P478

Q39389586-12EE5537-F3B7-425D-8656-5C4593FC052C

P50

Q39389586-2F621229-50FC-46EA-9946-20362D0E9345

P577

Q39389586-44AC5296-A1B8-4D20-A48B-508FD9B61B39

P698

Q39389586-B55D4D06-C83D-431C-8B94-D9E4BEEBE0EF

P356

P1433

Bioconjugate Chemistry

P1476

68Ga-complex lipophilicity and ...... SMA inhibitor for PET imaging.

@en

P2093

Carmen Wängler

http://www.w3.org/2001/XMLSchema#string

Martin Schäfer

http://www.w3.org/2001/XMLSchema#string

Matthias Eder

http://www.w3.org/2001/XMLSchema#string

Michael Eisenhut

http://www.w3.org/2001/XMLSchema#string

Ulrike Bauder-Wüst

http://www.w3.org/2001/XMLSchema#string

Uwe Haberkorn

http://www.w3.org/2001/XMLSchema#string

William-Edmund Hull

http://www.w3.org/2001/XMLSchema#string

P304

688-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BC200279B

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22369515

http://www.w3.org/2001/XMLSchema#string